Trial Profile
A Multi-arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual Pi3k/Mtor Inhibitors Pf-04691502 And Pf-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary) ; Irinotecan (Primary) ; Mirdametinib (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 24 Oct 2017 Results published in the Targeted Oncology
- 13 May 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 13 May 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.